In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...
Read More
In a nutshell This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients. Some background Around 20% of patients present with advanced CRC at diagnosis....
Read More
In a nutshell This study was carried out to assess the effectiveness of metastasectomy (ME; surgical removal of tumors that have spread from the original tumor location) for patients with advanced melanoma who responded to targeted or immunotherapy. The authors found that ME for melanoma is associated with a longer overall survival (OS) in...
Read More
In a nutshell This study investigated the effects of bevacizumab (Avastin) combined with mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) treatment in RAS-positive advanced colorectal cancer (CRC). Researchers suggested that this treatment improved the treatment and survival outcomes of patients with CRC and liver metastasis (spread to the...
Read More
In a nutshell This study investigated the impact of hepatic artery infusion (HAI) after advanced colorectal cancer surgery in patients with liver metastasis. Researchers suggested that HAI is associated with improved outcomes in these patients regardless of KRAS mutation status. Some background Colorectal cancer is the third most common cancer...
Read More
In a nutshell This trial is aiming to examine the effectiveness of APG-115 with pembrolizumab (Keytruda) in the treatment of metastatic melanoma. The main outcomes to be measured will be the maximum dose tolerated and the overall response to the drug. This trial is recruiting in multiple locations in the United States. The details...
Read More
In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....
Read More
In a nutshell This phase 2 trial is examining the effectiveness of TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) in the treatment of metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured will be the overall response to the treatment rate. This study is being conducted in New Jersey, US. The details...
Read More
In a nutshell This trial was carried out to assess the effectiveness of anlotinib (AL3818) on different subtypes of non-small cell lung cancer (NSCLC). The trial demonstrated that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with adenocarcinoma (ACC) and tended to improve survival in...
Read More
In a nutshell This trial compared the effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) in treating metastatic breast cancer compared to lapatinib (Tykerb) plus capecitabine in patients who have received 2 or more treatment lines. The authors found that neratinib plus capecitabine (N+C) resulted...
Read More
In a nutshell The study evaluated treatment outcomes reported by patients with metastatic non-small-cell lung cancer (mNSCLC) who were treated by pembrolizumab (Keytruda) and pemetrexed (Alimta) and platinum chemotherapy. The authors found that adding pembrolizumab to pemetrexed-platinum chemotherapy improved health-related quality of life (HRQOL)...
Read More
In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...
Read More
